Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies

被引：4
|
作者：
Gressens, Simon B. [1 ]
Wiedemann, Aurelie [2 ,4 ]
Dechenaud, Marie [2 ]
Dupuis, Jehan [3 ]
Gallien, Sebastien [1 ,4 ]
Melica, Giovanna [1 ,4 ]
Haioun, Corinne [3 ,4 ]
Lemonnier, Francois [3 ,4 ]
Levy, Yves [1 ,2 ]
机构：
[1] Univ Paris Est Creteil, Hop Univ Henri Mondor, AP HP, Infect Dis & Immunol Dept, Creteil, France
[2] Univ Paris Est Creteil, Vaccine Res Inst, Fac Med, Team 16,INSERM U955, Creteil, France
[3] Grp Hosp Univ Chenevier Mondor, Serv Unite Hemopathies Lymphoides, IAP HP, F-94010 Creteil, France
[4] Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France
来源：
VACCINE | 2023年 / 41卷 / 09期
关键词：
Third dose; COVID-19; Immunocompromised; Vaccine; T cell responses; Hematological malignancies; SARS-COV-2; IMMUNITY;
D O I：
10.1016/j.vaccine.2023.01.064
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vac-cine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 ther-apies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4+Th1+T cell responses while the effect CD8 + T cell responses was marginal. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1550 / 1553
页数：4
相关论文
共 50 条
  • [31] Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies
    Gurion, Ronit
    Rozovski, Uri
    Itchaki, Gilad
    Gafter-Gvili, Anat
    Leibovitch, Chiya
    Raanani, Pia
    Ben-Zvi, Haim
    Szwarcwort, Moran
    Taylor-Abigadol, Mor
    Dann, Eldad J.
    Horesh, Nurit
    Inbar, Tsofia
    Tzoran, Inna
    Lavi, Noa
    Fineman, Riva
    Ringelstein-Harlev, Shimrit
    Horowitz, Netanel A.
    HAEMATOLOGICA, 2022, 107 (03) : 715 - 720
  • [32] Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naive and previously infected individuals
    Cavic, Milena
    Nesic, Andrijana
    Martinovic, Katarina Mirjacic
    Vuletic, Ana
    Zizak, Irina Besu
    Miletic, Nevena Tisma
    Krivokuca, Ana
    Jankovic, Radmila
    Gavrovic-Jankulovic, Marija
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [33] Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
    Lo Sasso, Bruna
    Agnello, Luisa
    Giglio, Rosaria Vincenza
    Gambino, Caterina Maria
    Ciaccio, Anna Maria
    Vidali, Matteo
    Ciaccio, Marcello
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [34] Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
    Bruna Lo Sasso
    Luisa Agnello
    Rosaria Vincenza Giglio
    Caterina Maria Gambino
    Anna Maria Ciaccio
    Matteo Vidali
    Marcello Ciaccio
    Scientific Reports, 12
  • [35] Evaluation of T and B lymphocytes subsets after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccination in hematopoietic stem cell transplantation patients
    Attolico, I.
    Tarantini, F.
    Schifone, C. P.
    Mestice, A.
    De Tullio, G.
    Derosa, C.
    Carbone, F.
    Carluccio, P.
    Delia, M.
    Albano, F.
    Larocca, A. M. V.
    Stefanizzi, P.
    Vimercati, L.
    Tafuri, S.
    Musto, P.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 64 - 64
  • [36] Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naive BNT162b2 vaccine recipients
    Azzi, Lorenzo
    Focosi, Daniele
    Dentali, Francesco
    Baj, Andreina
    Maggi, Fabrizio
    VACCINE, 2021, 39 (18) : 2489 - 2490
  • [37] Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study
    Montori, Michele
    Martini, Francesco
    DE Blasio, Federico
    Buono, Tiziana
    Quatraccioni, Claudia
    Guardati, Paola
    Calzolari, Manuela
    Rossi, Chiara
    Bendia, Emanuele
    Menzo, Stefano
    Valenza, Carmine
    Pellicano, Rinaldo
    Maroni, Luca
    Benedetti, Antonio
    MINERVA GASTROENTEROLOGY, 2023, 69 (02): : 268 - 276
  • [38] Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors
    Venerito, V.
    Stefanizzi, P.
    Martinelli, A.
    Fornaro, M.
    Galeone, M. G.
    Tafuri, S.
    Iannone, F.
    Lopalco, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (01) : 166 - 169
  • [39] Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
    Yanay, Noa Berar
    Freiman, Sarit
    Shapira, Ma'anit
    Wishahi, Samar
    Hamze, Munir
    Elhaj, Mohamad
    Zaher, Maha
    Armaly, Zaher
    KIDNEY INTERNATIONAL, 2021, 99 (06) : 1496 - 1498
  • [40] Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
    Salvagno, Gian Luca
    Lippi, Giuseppe
    VACCINES, 2022, 10 (06)
12345